SCHEMBL17504497

SCHEMBL17504497

COC(=O)CC(N)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
HSD17B10 Q99714 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
TET2 Q6N021 1/20 0.35
SLC1A1 P43005 1/20 0.35
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
RECQL P46063 1/20 0.34
BIRC2 Q13490 1/20 0.33
CYP2D6 P10635 1/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 2/20 0.31
RAB9A P51151 1/20 0.31
CA12 O43570 2/20 0.31
CA14 Q9ULX7 2/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15774515 1.00 TSHR (0.40) TSHRHSD17B10MGAMGAASI
SCHEMBL14685074 1.00 TSHR (0.40) TSHRHSD17B10MGAMGAASI
Hydrochloric Acid SCHEMBL16760762 0.98 TSHR (0.39) TSHRHSD17B10MGAMGAASI
Hydrochloric Acid SCHEMBL15774514 0.98 TSHR (0.39) TSHRHSD17B10MGAMGAASI
Hydrochloric Acid SCHEMBL14677955 0.98 TSHR (0.39) TSHRHSD17B10MGAMGAASI
Hydrochloric Acid SCHEMBL28180974 0.98 TSHR (0.39) TSHRHSD17B10MGAMGAASI
SCHEMBL9744364 0.82
SCHEMBL19226139 0.81 TSHR (0.36) TSHRHSD17B10MGAMGAASI
SCHEMBL15671106 0.80 TSHR (0.39) TSHRHSD17B10MGAMGAASI
SCHEMBL544794 0.80 CYP2D6 (0.46) GAACYP2D6MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113004252-B Aryl imidazole derivative and application thereof 江苏先声药业有限公司 2023-06-09 CN disclosed
EP-3362451-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
CN-106661036-B Pyrrolopyrimidines for use in influenza virus infection 爱尔兰詹森科学公司 2022-03-15 CN disclosed
CN-110446711-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2022-02-15 CN disclosed
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-01-18 US disclosed
CN-109641868-B Inhibitors of influenza virus replication and methods of use and uses thereof 广东东阳光药业有限公司 2021-12-03 CN disclosed
CN-113004252-A Aryl imidazole derivative and application thereof 江苏先声药业有限公司 2021-06-22 CN disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 US disclosed
CN-109748915-B Inhibitors of influenza virus replication and methods of use and uses thereof 广东东阳光药业有限公司 2021-03-26 CN disclosed
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-09-07 US disclosed
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-09-07 US disclosed
US-20170226102-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-08-10 US disclosed
US-20170226102-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-08-10 US disclosed
EP-3191489-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION Janssen Sciences Ireland UC (IE) 2017-07-19 EP disclosed
WO-2017097234-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-06-15 WO disclosed
EP-3177609-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION Janssen Sciences Ireland UC (IE) 2017-06-14 EP disclosed
WO-2016037953-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN SCIENCES IRELAND UC (IE) 2016-03-17 WO disclosed
WO-2016020526-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN SCIENCES IRELAND UC (IE) 2016-02-11 WO disclosed
WO-2016020526-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN SCIENCES IRELAND UC (IE) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT TSHR 4049/4885HSD17B10 4477/4885MGAM 1994/4885
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof POLRMT, EIF2AK2, POLM TSHR 3992/4885HSD17B10 4314/4885MGAM 1859/4885
US-20170226102-A1 INDOLES FOR USE IN INFLUENZA VIRUS INFECTION IDO1, IDO2, INMT TSHR 1379/4885HSD17B10 2076/4885MGAM 2035/4885
US-20170253600-A1 PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION IMPDH1, IMPDH2, TYMP TSHR 2781/4885HSD17B10 2940/4885MGAM 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.